What Prime Medicine, Inc. told the SEC could break it.

Prime Medicine's operations are concentrated in Massachusetts and it acknowledges it has not undertaken a systematic analysis of the potential consequences to its business from a major flood, power loss, terrorist activity or other natural disaster and does not have a recovery plan for such events; a disaster, business disruption or other event affecting its single-region facilities could interrupt its research, lab and manufacturing-support operations and materially harm its development programs.

“Our facilities are located in Massachusetts. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity or other natural disasters and do not have a recovery plan for such events.”

Prime Medicine depends on third parties across its value chain: a CRO conducted its PM359 clinical trial and CROs will conduct some or all future trials, and it relies on third parties for cGMP manufacturing/testing of its early-stage and potential commercial genetic-medicine supplies (it has not yet decided whether to build in-house cGMP capacity); it also depends on its licensors (including the Broad Institute, source of its in-licensed Prime Editing patent estate) to pay fees and prosecute/maintain those patents, so underperformance, capacity constraints or loss of these third-party relationships could delay its programs or weaken its IP position.

“a CRO conducted our clinical trial for PM359, and CROs will conduct some or all of our future clinical trials.”

Prime Medicine faces broad regulatory and policy risk: its value depends on obtaining FDA (and foreign) approval for novel Prime Editing therapies; U.S. drug-pricing actions (the Inflation Reduction Act, CMS's proposed most-favored-nation 'GLOBE' rebates for Part B, and the eliminated Medicaid rebate cap) could pressure future prices; the administration's announced 100% tariff on brand-name/patented drugs (currently on hold) unless companies expand U.S. manufacturing could disrupt its supply chain; and the proposed BIOSECURE Act could restrict its use of Chinese biotech companies and CROs for preclinical/clinical work.

“For example, on September 25, 2025, the current U.S. administration announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S., and may impose more restrictions on goods. Although the pharmaceutical tariff is currently on hold, this could have a material adverse effect on our supply chain and business prospects as well as the larger biopharmaceutical industry.”

Prime Medicine has generated no revenue from product sales and does not expect to until it completes preclinical/clinical development, obtains regulatory approval and commercializes a Prime Editing product candidate — which it cannot assure will ever occur — while it expects expenses to increase substantially; its revenue to date has come only from research-collaboration and license agreements, so it depends on continued access to capital (e.g., a $300 million at-the-market equity program and collaboration funding) and a funding shortfall would force it to delay, scale back or halt programs.

“To date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until we successfully complete preclinical and clinical development of, receive regulatory approval for, and commercialize a product candidate and we do not know when, or if at all, that will occur.”